No Data
No Data
No Data
No Data
No Data
Mizuho Maintains Buy on Adverum Biotechnologies, Lowers Price Target to $22
Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies with a Buy and lowers the price target from $40 to $22.
Analyst Upgrades4minutes ago
Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the compan
BenzingaApr 26 04:40
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
BenzingaApr 24 04:31
Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?
Yahoo FinanceApr 23 21:40
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
Yahoo FinanceApr 4 21:40
Analysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)
TipRanksMar 28 09:50
No Data
No Data